A Case Series of a Luteolin Formulation (Neuroprotek®) in Children with Autism Spectrum Disorders
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
There has been an impressive, little understood increase in cases of Autism Spectrum Disorders (ASD). The lack of any distinctive pathogenetic mechanism has hampered the development of any effective treatments. Increasing evidence indicates oxidative stress, brain inflammation, gastrointestinal (GI) dysfunction and allergic symptoms may be present in ASD patients. The flavone luteolin has antioxidant, anti-flammatory, anti-allergy and neuroprotective properties. Given these findings, a dietary supplement was developed with a unique mixture of luteolin with the related flavonoids quercetin and rutin in a liposomal formulation of olive kernel oil (OKO), which increases their absorption. Results are presented for children with ASD (n=37, 4–14 years old) who had not obtained any benefit from multiple other regimens and who used this formulation for at least 4 months. GI and allergy symptoms improved in about 75% of children, eye contact and attention in 50%, social interaction in 25% and resumption of speech in about 10%. There were no adverse effects. Even though these results represent an uncontrolled open case series, they are encouraging because they suggest good tolerability and potential effectiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroglial activation and neuroinflammation in the brain of patients with autism
Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W., & Pardo, C. A. (2005) · Annals of Neurology · doi:10.1002/ana.20315 · Cited by 2,149 · cited 1×
“Postmortem brains of ASD patients had evidence of microglial activation and inflammation (16).”
BackgroundIdentification and Evaluation of Children With Autism Spectrum Disorders
Johnson, C. P., Myers, S. M., & and the Council on Children With Disabilities (2007) · Pediatrics · doi:10.1542/peds.2007-2361 · Cited by 2,011
The development of allergic inflammation
Galli, S. J., Tsai, M., & Piliponsky, A. M. (2008) · Nature · doi:10.1038/nature07204 · Cited by 1,839 · cited 1×
“Role ofmast cells Mast cells are critical for the development of allergies (8), inflammation (9), and autism (10) because they can secrete a plethora of vasoactive and inflammatory mediators that include histamine, kinins, and tryptase (preformed), as well as”
BackgroundMaternal Immune Activation Alters Fetal Brain Development through Interleukin-6
Smith, S. E. P., Li, J., Garbett, K., Mirnics, K., & Patterson, P. H. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2178-07.2007 · Cited by 1,605
Evidence-Based Comprehensive Treatments for Early Autism
Rogers, S. J., & Vismara, L. A. (2008) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374410701817808 · Cited by 984
Elevated immune response in the brain of autistic patients
Li, X., Chauhan, A., Sheikh, A. M., Patil, S., Chauhan, V., Li, X.-M., Ji, L., Brown, T., & Malik, M. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2008.12.002 · Cited by 786
The immune response in autism: a new frontier for autism research
Ashwood, P., Wills, S., & Van de Water, J. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1205707 · Cited by 528 · cited 1×
“Brain inflammation in ASD Increasing evidence indicates that there is some immune dysfunction in ASD (15).”
BackgroundKing, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., Bregman, J. D., Donnelly, C. L., Anagnostou, E., Dukes, K., Sullivan, L., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.30 · Cited by 482
Gurney, J. G., McPheeters, M. L., & Davis, M. M. (2006) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.160.8.825 · Cited by 411 · cited 1×
“Autism Spectrum Disorders (ASD) are pervasive developmehtal disorders, diagnosed in early childhood (l) that have increased more than 10fold during the last decade to approximately 1/100 live births (2).”
BackgroundA Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders
McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., & Veenstra-VanderWeele, J. (2011) · Pediatrics · doi:10.1542/peds.2011-0427 · Cited by 356 · cited 1×
“In fact, recent studies have shown that use of selective serotonin reuptake inhibitor (SSRI) antidepressants (5) and some antipsychotics (6) may actually worsen ASD symptoms and cause the onset of adverse effects (7).”
Background
Cited by
Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies
Aziz, N., Kim, M.-Y., & Cho, J. Y. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.05.019 · Cited by 642
Astrocyte-oligodendrocyte interaction regulates central nervous system regeneration
Molina-Gonzalez, I., Holloway, R. K., Jiwaji, Z., Dando, O., Kent, S. A., Emelianova, K., Lloyd, A. F., Forbes, L. H., Mahmood, A., Skripuletz, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39046-8 · Cited by 176
Immunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy
Marchezan, J., Winkler dos Santos, E. G. A., Deckmann, I., & Riesgo, R. D. S. (2018) · Neuroimmunomodulation · doi:10.1159/000492225 · Cited by 70
Nadeem, A., Ahmad, S. F., Attia, S. M., AL-Ayadhi, L. Y., Bakheet, S. A., & Al-Harbi, N. O. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.12.002 · Cited by 63
“gested by previous animal and clinical report which have displayed improvement of autistic symptoms through reduction in oxidants and inflammatory cytokines (Singh et al., 2014; Tsilioni et al., 2015; Theoharides et al., 2012; Parker-Athill et al., 2009; Bakheet et al., 2017).”
Metadata
- Authors
- Theoharides, T. C., Asadi, S., & Panagiotidou, S.
- Venue
- International Journal of Immunopathology and Pharmacology
- Publisher
- SAGE Publications
- Published
- 2012-04
- Volume
- 25
- Issue
- 2
- Pages
- 317-323
- ISSN
- 0394-6320 (ISSN-L)
- 2058-7384
- OpenAlex
- W1505731461
- Cited by
- 120
- References
- 13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Case Series of a Luteolin Formulation (Neuroprotek®) in Children with Autism Spectrum Disorders. https://app.cochat.ai/papers/10.1177/039463201202500201
- The paper
- Theoharides, T. C., Asadi, S., & Panagiotidou, S. (2012). A Case Series of a Luteolin Formulation (Neuroprotek®) in Children with Autism Spectrum Disorders. International Journal of Immunopathology and Pharmacology. https://doi.org/10.1177/039463201202500201
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.